Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Temporal trends in oropharyngeal cancer treatment and survival: 1998-2009.

Chen AY, Zhu J, Fedewa S.

Laryngoscope. 2014 Jan;124(1):131-8. doi: 10.1002/lary.24296. Epub 2013 Aug 5.

PMID:
23832649
2.

Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma.

Self EM, Bumpous J, Ziegler C, Wilson L, Potts K.

JAMA Otolaryngol Head Neck Surg. 2013 Apr;139(4):356-61. doi: 10.1001/jamaoto.2013.103.

PMID:
23599070
3.

Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.

Haughey BH, Sinha P.

Laryngoscope. 2012 Sep;122 Suppl 2:S13-33. doi: 10.1002/lary.23493.

PMID:
22926949
4.

Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007.

Chen AY, Fedewa S, Zhu J.

Arch Otolaryngol Head Neck Surg. 2011 Oct;137(10):1017-24. doi: 10.1001/archoto.2011.171.

PMID:
22006780
5.

Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.

Krstevska V, Stojkovski I, Zafirova-Ivanovska B.

Radiat Oncol. 2012 May 28;7:78. doi: 10.1186/1748-717X-7-78.

6.

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK, Conway DI; CSROC Expert Panel.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD006386. doi: 10.1002/14651858.CD006386.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(4):CD006386.

PMID:
20824847
7.

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK, Conway DI.

Cochrane Database Syst Rev. 2011 Apr 13;(4):CD006386. doi: 10.1002/14651858.CD006386.pub3. Review.

PMID:
21491393
8.

Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience.

Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA.

Head Neck. 2011 Oct;33(10):1433-40. doi: 10.1002/hed.21615. Epub 2010 Nov 10.

PMID:
21928415
9.

Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas.

Sedaghat AR, Zhang Z, Begum S, Palermo R, Best S, Ulmer KM, Levine M, Zinreich E, Messing BP, Gold D, Wu AA, Niparko KJ, Kowalski J, Hirata RM, Saunders JR, Westra WH, Pai SI.

Laryngoscope. 2009 Aug;119(8):1542-9. doi: 10.1002/lary.20533.

PMID:
19522004
10.

Changes in treatment of advanced oropharyngeal cancer, 1985-2001.

Chen AY, Schrag N, Hao Y, Stewart A, Ward E.

Laryngoscope. 2007 Jan;117(1):16-21.

PMID:
17202924
11.

National trends in oropharyngeal cancer surgery and the effect of surgeon and hospital volume on short-term outcomes and cost of care.

Gourin CG, Frick KD.

Laryngoscope. 2012 Mar;122(3):543-51. doi: 10.1002/lary.22447. Epub 2012 Jan 12.

PMID:
22241647
12.

Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.

Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1823-30. doi: 10.1016/j.ijrobp.2010.10.053. Epub 2011 May 5.

PMID:
21549516
13.

Functional outcomes after treatment of advanced oropharyngeal carcinoma with radiation or chemoradiation.

Myers C, Kerr P, Cooke A, Bammeke F, Butler J, Lambert P.

J Otolaryngol Head Neck Surg. 2012 Apr;41(2):108-18.

PMID:
22569011
14.

Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation.

Shoultz-Henley S, Garden AS, Mohamed AS, Sheu T, Kroll MH, Rosenthal DI, Gunn GB, Hayes AJ, French C, Eichelberger H, Kalpathy-Cramer J, Smith BD, Phan J, Ayoub Z, Lai SY, Pham B, Kies M, Gold KA, Sturgis E, Fuller CD.

Int J Cancer. 2016 Mar 1;138(5):1290-7. doi: 10.1002/ijc.29870. Epub 2015 Oct 9.

PMID:
26414107
15.

Postoperative failure of platelet recovery is an independent risk factor for poor survival in patients with oral and oropharyngeal cancer.

Perisanidis C, Mittlböck M, Schoppmann A, Kornek G, Starlinger P, Stift A, Selzer E, Schopper C, Ewers R.

Clin Oral Investig. 2013 Apr;17(3):913-9. doi: 10.1007/s00784-012-0755-8. Epub 2012 May 29.

PMID:
22643871
16.
17.

Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.

Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, Kraus D, Shah J, Zelefsky M, Pfister D, Lee N.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):915-22. doi: 10.1016/j.ijrobp.2010.07.008. Epub 2010 Oct 13.

PMID:
20947269
18.

Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.

Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L.

Ann Oncol. 2012 Jul;23(7):1832-7. doi: 10.1093/annonc/mdr544. Epub 2011 Nov 24.

19.

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA.

J Clin Oncol. 2010 Sep 20;28(27):4142-8. doi: 10.1200/JCO.2010.29.2904. Epub 2010 Aug 9.

20.

A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.

Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74.

PMID:
17145527
Items per page

Supplemental Content

Write to the Help Desk